RxDoctor Payments Data

Benjamin Trichon, MD

Advanced Heart Failure and Transplant Cardiology · Asheville, NCNPI 1871599860

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $24,270 of the $37,298 with a category attached, or 65.1%. 21 manufacturers reported payments, led by Actelion Pharmaceuticals US, Inc. at 47.6% of the total. Reporting peaked in 2019 at $17,802 and has fallen 96.6% since, to $607 in 2025.

$37,298in general payments, 2019–2025

Across 330 payments — averaging $113.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Actelion Pharmaceuticals US, Inc.$18K
  • Novartis$10K
  • Abbott$7K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$444
  • Pfizer$357
  • Abiomed$314
  • plus $2K from 15 others
$195,685in research payments, 2019–2025

Across 165 payments — averaging $1185.97 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Boehringer Ingelheim Pharma GmbH & Co.kg$55K
  • United Therapeutics Corporation$42K
  • Amgen$37K
  • Boehringer Ingelheim International GmbH$34K
  • American Regent$28K

What the payments were for

  • Consulting fees$2,8358%
  • Speaking & faculty fees$24,27065%
  • Travel & lodging$2,0736%
  • Food & beverage$8,10922%
  • Education$110%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$37,298 in reported general payments places this provider in the 60th percentile of 31 advanced heart failure and transplant cardiology providers in North Carolina.

See all advanced heart failure and transplant cardiology providers in North Carolina

Medicare billing

Part B allowed, 2024
$122,394
Medicare patients
323
Services billed
1,295

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Tyvaso DpiTreprostinil95$2,205,773
OpsumitMacitentan168$2,100,220
VyndamaxTafamidis78$1,765,279
AdempasRiociguat122$1,624,405
UptraviSelexipag60$1,417,509
Orenitram ErTreprostinil Diolamine84$1,126,764
CamzyosMavacamten86$702,916
JardianceEmpagliflozin327$320,995
EntrestoSacubitril/Valsartan258$315,065
Ambrisentan111$303,143
EliquisApixaban276$249,805
LetairisAmbrisentan14$181,728
FarxigaDapagliflozin Propanediol77$61,855
AdcircaTadalafil13$54,210
Sildenafil Citrate123$26,490

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi$17,751$3,517,728228 claims
PfizerVyndamax, Eliquis$357$2,015,084354 claims
BayerAdempas$83$1,624,405122 claims
E.r. Squibb & Sons, L.L.C.Camzyos$130$702,91686 claims
Boehringer IngelheimJardiance$124$320,995327 claims
NovartisEntresto$9,834$315,065258 claims
AstraZenecaFarxiga$138$61,85577 claims
United Therapeutics CorporationAdcirca$246$54,21013 claims
Novo NordiskOzempic$40$13,64511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 31 advanced heart failure and transplant cardiology providers in North Carolina.

Other advanced heart failure and transplant cardiology in Asheville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →